Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AstraZeneca Begins Olaparib Phase III Trial; Reverses $285 Mln Charge

AstraZeneca PLC (AZN.L,AZN: Quote) Wednesday said it enrolled the first patient in the Phase III SOLO, or Study of OLaparib in Ovarian cancer, programme. Olaparib, an innovative oral poly ADP ribose polymerase inhibitor is being investigated for the treatment of BRCA mutated ovarian cancer in SOLO. The clinical development is designed to study the benefit, progression free survival, of olaparib as a maintenance monotherapy in BRCA mutated ovarian cancer patients who are in complete or partial response following platinum-based chemotherapy in the first line setting, SOLO 1, and relapsed setting, SOLO 2.

A pre-tax impairment charge of $285 million, which was incurred in December 2011 after deciding not to progress olaparib into phase III, will be reversed in the third quarter of 2013, following the start of the programme. This reversal will be excluded from the core earning per share, the company said.

The SOLO 1 study is being conducted in collaboration with the Gynecologic Oncology Group and the SOLO 2 study with the European Network of Gynaecological Oncological Trial Groups. Both trials are randomised, double blind, placebo controlled studies that utilise the tablet formulation of olaparib at a dose of 300mg twice daily.

Separately, Myriad Genetics, Inc. (MYGN) said it is expanding its collaboration agreement with AstraZeneca to provide companion diagnostics for the olaparib Phase 3 clinical development program. Pursuant to the agreement, Myriad will build out a new laboratory within its Salt Lake City facility in accordance with U.S. Food and Drug Administration regulations for companion diagnostic devices.

Register
To receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumers spent less in July than in the previous month, a surprise retreat that complicates the prevailing belief that the U.S. economic situation is improving. Along with the unexpected drop in spending, government figures released on Friday showed that incomes rose at a slower pace in July than in the previous month. Meanwhile, data on prices indicated that inflation pressures remain tame. India's economy grew faster-than-expected in the three months to June and at the strongest pace in two years, preliminary figures from the Central Statistics Office revealed Friday. Gross domestic product grew 5.7 percent in the April to June quarter, which exceeded economists' forecast for 5.5 percent expansion. The economy grew 4.6 percent in the previous three months. Eurozone inflation slowed as expected in August on falling energy prices giving room for the central bank to support demand and economic recovery without stoking inflation and help the region to create more jobs. The unemployment rate remained unchanged at an elevated level in July. Nonetheless, it was at the lowest since September 2012.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.